– Strong preclinical data shows that C21 reverses vascular remodelling – Proof-of-concept trial in pulmonary arterial hypertension (“PAH”) planned to start late 2022 – Appointment of two new senior clinical advisors in PAH GOTHENBURG, Sweden, March 9, 2022 /PRNewswire/ — Vicore Pharma Holding AB (publ) (“Vicore”), a clinical-stage pharmaceutical company developing medicines targeting […]